Cannabinoid Formulation Synergy for Depression and Sleep
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, anxiety, and PTSD, as well as sleep aids, have limited effectiveness and options, with cannabinoids like CBD and CBC showing promise but their potential in combination formulations for these conditions has not been fully explored.
Innovation Solution
A cannabinoid formulation comprising cannabidiol (CBD), cannabichromene (CBC), and optionally tetrahydrocannabinol (THC), in specific weight ratios, is developed for managing depression, anxiety, PTSD, and aiding sleep, utilizing various delivery forms such as pills, capsules, and oil-based sprays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for depression, anxiety, and PTSD are used, then treatment options are available, but effectiveness is limited
Solution Approach 1:
The patent combines multiple cannabinoids (CBD, CBC, and optionally THC) in specific ratios to create a formulation that leverages the synergistic effects of each component. CBD provides anxiolytic and antidepressant effects through 5HT1A receptor mediation and anandamide metabolism inhibition, while CBC contributes through CB2 receptor affinity and TRPA1 channel activation, and THC provides CB1/CB2 agonistic activity. This combination resolves the contradiction by merging multiple therapeutic agents to achieve both enhanced effectiveness and expanded treatment versatility for depression, anxiety, and PTSD.
2Reliability
If single cannabinoid formulations (CBD or CBC alone) are used, then the formulation is simple, but the therapeutic effect is insufficient
Solution Approach 1:
The patent creates a composite cannabinoid formulation where CBD, CBC, and optionally THC are combined in specific weight ratios (CBD 5-50mg, CBC 5-50mg, THC 0.1-10mg). This composite approach allows the formulation to achieve superior therapeutic effects by leveraging the complementary pharmacological mechanisms of each cannabinoid: CBD's 5HT1A mediation and anandamide preservation, CBC's CB2 affinity and TRPA1 activation, and THC's CB1/CB2 agonism. The specific ratio optimization ensures synergistic interaction while maintaining manageable formulation complexity.
3Reliability
If higher dosages of THC and CBD are used to achieve therapeutic effects, then the therapeutic effect is improved, but the dosage required increases
Solution Approach 1:
The patent reduces the required dosage of individual cannabinoids by combining them in synergistic ratios. The formulation uses CBD (5-50mg) with CBC (5-50mg) and optional THC (0.1-10mg), where each component enhances the therapeutic effect of the others. CBD's anxiolytic effects through 5HT1A receptors and anandamide metabolism inhibition work synergistically with CBC's CB2-mediated anti-inflammatory effects and TRPA1 channel activation, allowing lower dosages to achieve the same or better therapeutic outcomes compared to single cannabinoid formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation demonstrates anxiolytic, antidepressant, and anti-inflammatory effects, providing additive or synergistic benefits at CB1 and CB2 receptor levels, potentially reducing the dosage of THC and CBD required, and offering pharmacological advantages over conventional therapies.
Implementation Method 1
CBD is suggested for its anxiolytic and antidepressant effects in patients with generalized social anxiety disorder. The underlying pharmacological mechanism of the anxiolytic/antidepressant properties of CBD are suggested to be 5HT1A receptor-mediated neurotransmission. Δ9-THC exerts partial agonistic activity on CB1 and CB2 receptors with high binding affinity with CB1 receptor leading to its psychoactive activity.
Implementation Method 2
The underlying pharmacological mechanism of the anxiolytic/antidepressant properties of CBD are suggested to be 5HT1A receptor-mediated neurotransmission, as well as, inhibition of anandamide metabolism and activation of TRPV1 receptor channels that facilitate CB1- and CB2-mediated responses. CBC was found to be the most potent agonist of all the phytocannabinoids at TRPA1 channels.
Implementation Method 3
CBD has been observed to act synergistically with Δ9-THC and contribute to the analgesic effect of medicinal-based cannabis extract. The agonistic activity of CBC with CB1 and CB2 receptors may offer a promising approach to potentiate the effect of other cannabinoids that exert their activities via binding and activation of CB1 and CB2 receptors.
Data Source
AI summary
Formulations and methods for managing depression, anxiety and/or PTSD are described, for use by individuals in need thereof. The formulations comprise a plurality of cannabinoids and one or more excipient, diluent or carrier. The cannabinoids are present in the formulation in optimized amounts to address these conditions in an amount of: tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) as primary cannabinoids in a weight ratio of from 0-1:4-20:10-25, respectively, such as 1:5:20, 0:20:10 or 0:10:20. Formulations and methods for aiding sleep are also described, for use by individuals in need thereof, such as individuals with insomnia. The formulation comprises a plurality of cannabinoids and one or more excipient, diluent or carrier. The formulation comprises tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) as primary cannabinoids in a weight ratio of from 1:0-5:15-25, respectively, such as 1:3:20, 1:0:20 or 1:4:20.